key: cord-0896825-zgbajga8
authors: Klausberger, Miriam; Kienzl, Nikolaus F.; Stadlmayr, Gerhard; Grünwald‐Gruber, Clemens; Laurent, Elisabeth; Stadlbauer, Katharina; Stracke, Florian; Vierlinger, Klemens; Hofner, Manuela; Manhart, Gabriele; Gerner, Wilhelm; Grebien, Florian; Weinhäusel, Andreas; Mach, Lukas; Wozniak‐Knopp, Gordana
title: Designed SARS‐CoV‐2 receptor binding domain variants form stable monomers
date: 2022-02-03
journal: Biotechnol J
DOI: 10.1002/biot.202100422
sha: 0b0d0bd5ad7b9282eea85179ede4ea97809f0545
doc_id: 896825
cord_uid: zgbajga8

The receptor binding domain (RBD) of the SARS‐CoV‐2 spike (S)‐protein is a prime target of virus‐neutralizing antibodies present in convalescent sera of COVID‐19 patients and thus is considered a key antigen for immunosurveillance studies and vaccine development. Although recombinant expression of RBD has been achieved in several eukaryotic systems, mammalian cells have proven particularly useful. The authors aimed to optimize RBD produced in HEK293‐6E cells towards a stable homogeneous preparation and addressed its O‐glycosylation as well as the unpaired cysteine residue 538 in the widely used RBD (319‐541) sequence. The authors found that an intact O‐glycosylation site at T323 is highly relevant for the expression and maintenance of RBD as a monomer. Furthermore, it was shown that deletion or substitution of the unpaired cysteine residue C538 reduces the intrinsic propensity of RBD to form oligomeric aggregates, concomitant with an increased yield of the monomeric form of the protein. Bead‐based and enzyme‐linked immunosorbent assays utilizing these optimized RBD variants displayed excellent performance with respect to the specific detection of even low levels of SARS‐CoV‐2 antibodies in convalescent sera. Hence, these RBD variants could be instrumental for the further development of serological SARS‐CoV‐2 tests and inform the design of RBD‐based vaccine candidates.

In the SARS-CoV-2 outbreak of 2019, there was an urgent need to rapidly develop reagents that would serve as components of serological diagnostic tests. [1, 2] The detection of specific antibodies in serum samples complements PCR-based infection diagnosis in delivering evidence of past infections and allows the determination of the extent of vaccination responses. Molecules selected for diagnostic purposes typically represent parts of the respective virus coat protein carrying antigenic determinants. Apart from exhibiting exquisite specificity, these proteins should feature cost-effective production yields and high biophysical stability. [3] The critical point of infection with SARS-CoV-2 has early been established as the interaction of the viral S-protein with its cellular receptor angiotensin-converting enzyme 2 (ACE2). [4] This complex viral protein is conformationally highly variable, [5] and its sequence contains up to 22 potentially used N-linked glycosylation sites, which renders it a challenging target for heterologous expression. [6] The amino acid residues in the S-protein that are actually involved in the interaction with ACE2 could be narrowed down to a region referred to as the receptor binding motif (RBM), [7] which is part of an independently folding and mostly solvent-exposed fragment termed the receptor binding domain (RBD). [8] Importantly, the RBD can be expressed at much higher yields (up to 90 mg L -1 ) [9] than the full-length S-protein ectodomain (1-2 mg L -1 ) in various eukaryotic expression systems [10] and therefore appears to be a promising vaccine candidate. [11] The first variants of RBD produced for structural characterization and diagnostic applications consisted of S-residues 319-541 (numbering as in PDB: 6VXX). As C538 forms a disulfide bond with C590 in the full-length S-protein (PDB: 6VXX), [12] the unpaired cysteine in recombinant RBD forms could lead to inadvertent dimer formation. The resulting protein preparations might thus contain multiple oligomeric species with distinct sets of properties. Dimers and higher-order multimers can skew the results of serological tests as well as the outcome of antigen quality assessments such as receptorbinding studies by surface plasmon resonance spectroscopy or bio-layer interferometry. Typically, multimeric protein forms are removed by preparative size-exclusion chromatography (SEC), hence a lower proportion of dimeric species in the starting material could lead to a higher yield of the final product.

From the collection of expression systems so far used to produce SARS-CoV-2 RBD (which includes prokaryotic, [13] yeast, [14] plant, [15] insect [1, 10] and mammalian cell systems [10, 16] ), human embryonic kidney HEK293 cells scored as the most potent system for production of an antigen suitable for diagnostic procedures. HEK293-produced RBD is typically N-glycosylated at two sites, displaying complex-type N-glycosylation at N331 and N343 (PDB: 6M17). [8] The "glycan shield" modulates the structural dynamics of RBD and is hence critical for viral infectivity. [17] Glycan moieties at these two positions can critically influence the expression and folding of recombinant RBD, which was demonstrated for RBD produced in bacteria [13] and yeast, [14] where lack of glycosylation or hyper-mannosylation respectively, influenced the quaternary status of the protein and its antigenic properties. Additional heterogeneity of recombinant RBD can arise from Oglycosylation. Up to six such glycosylation sites were found to be utilized in HEK293-expressed RBD, although only T323 showed substantial occupancy. [18] In the present work, we aimed to produce RBD variants that are less prone to form dimers, but are not negatively impacted in expression, thermostability, storage stability and their receptor and antibody binding properties. We hypothesized that this could be achieved by deletion or substitution of the unpaired cysteine C538. We also addressed the functional relevance of RBD O-glycosylation by replacing residue T323 with alanine to obliterate the major O-glycosylation site. Validation of respective protein sequences and analysis of N-and O-glycosylation patterns was performed using mass spectrometry-based peptide mapping. We also examined the quaternary status, stability, and hydrophobic properties of the RBD mutants, and determined the extent of their reactivity with ACE2 in vitro. The suitability of the resulting RBD variants for serological diagnosis was assessed with a large cohort of sera obtained from COVID-19 patients and non-infected individuals.

The PDB structure PDB:6VXX served as basis for the design of all RBD mutants. Removing the amino acid sequence C-terminal to residue K537, which could contribute to the stability of the domain by forming a salt bridge with E324, was the rationale for design of the shortened mutant tRBD (residues 319-537). Alternatively, the cysteine residue at position 538 was substituted with A, G, P, or S in RBD (319-541). Models were constructed using the FoldX plugin [19] in YASARA, [20] using the site mutagenesis tool with two energy minimization rounds at 298 K, pH 7, ionic strength 500 and van der Waals' design of 2. The Posi-tionScan function of the FoldX algorithm was applied to examine any possible destabilization. The solvent-accessible surface area (SASA) of C538 or its substitutions was determined using the PyMOL get_area function with solvent density set to 3.

The RBD sequence used corresponded to the genomic sequence of the Wuhan-Hu-1 isolate (GenBank: MN908947.3). [21] Mutants were produced in pTT28 vectors (Canadian National Research Council, CNRC) and were obtained using either directional cloning between the NheI and BstEII sites or site-directed mutagenesis with the Quikchange Lightning Mutagenesis kit (Agilent Technologies) using oligonucleotides listed in Table S1 , Supporting Information. Highquality plasmid DNA was prepared using the Nucleobond Xtra Midi kit analysis (Thermo Fisher Scientific) and stored at -80 • C until use.

Purified proteins were S-alkylated with iodoacetamide after reduction with DTT and then digested with LysC (Roche)/GluC (Promega) or trypsin (Promega). For assessment of the reactive state of individual cysteine residues, proteins were reacted with N-ethylmaleimide prior to treatment with DTT. Samples were analyzed using a maXis 4G ETD QTOF mass spectrometer (Bruker) as described [10] (details in Methods, Supporting Information).

Biophysical analyses 

Ten microgram protein were injected onto a Proteomix HIC Ethyl NP5 column (5 µm non-porous, 4.6 × 100 mm) (Sepax Technologies Inc.) with a Proteomix HIC Ethyl NP5 guard column (5 µm, 4 mm × 10 mm), and the chromatographic run was performed at a flow rate of 1 ml min -1 . First the column was equilibrated in 100% mobile phase A (25 mM Tris/HCl, pH 7.5, 1.5 M ammonium sulphate). After sample injection in 2.5 ml of 100% mobile phase A, the proteins were eluted with a linear gradient from 0% B to 100% B (25 mM Tris/HCl, pH 7.5, 20% v/v isopropanol) in 15 ml. After the application of 5 ml of 100% B, the column was re-equilibrated with a gradient from 0% A to 100% A in 10 ml, and rinsed with 21.5 ml 100% A.

A MicroCal PEAQ-DSC Automated system (Malvern Panalytical) was used to analyze 40 µM protein solutions in PBS at pH 7.5. The proteins were heated from 20 • C to 100 • C at a rate of 1 • C/min, cooled in situ and re-heated to obtain the baseline for subtraction from the first scan.

All measurements were performed in duplicates with proteins from dif-ferent expression batches. Fitting was done with Origin 7.0 for DSC software using the non-2-state transition model.

Accelerated stability assays SEC-purified monomeric RBD preparations were diluted to 50 µg ml -1 in PBS and incubated for 7 days at 25 • C. One hundred microliters of the samples were then analyzed with SEC-HPLC as described above. Additionally, 20 µl of each sample was analyzed by SDS-PAGE as described above. ELISA-based serological tests as well as statistical analysis of serological tests were performed as described previously [10] (details in Methods, Supporting Information).

The RBD construct most extensively described in the literature -RBD (319-541) -tends to form dimers when expressed in mammalian and insect cells as well as in plants. [1, 10] It has been noted that this could be due to the presence of an unpaired cysteine residue (C538) close to the C-terminus of the protein fragment. [22, 23] We used computational modeling to design a truncated RBD variant and single amino acid substitution mutants ( Figure 1A and Table S2 , Supporting Information). The calculated thermodynamic stability of the resulting proteins and the SASA of the modified residues deviated only minimally from the wild-type protein ( Figure 1B) . Furthermore, we mutated T323 F I G U R E 1 Molecular design of SARS-CoV-2 RBD variants: (A) structural models, left panel: wild-type RBD (319-541) with disulfide bridges and C538 in yellow and the salt bridge between E324 (red) and K537 (blue) highlighted; right panel: truncation mutant tRBD (319-537). The figure was prepared with PyMOL (Schrödinger LLC) using RBD coordinates from PDB:6VXX, (B) stability changes of point mutations and the calculated SASA of residue 538 determined for the individual mutants. n.a., not applicable to alanine to ablate the major O-glycosylation site. All truncated and mutated constructs could be expressed in HEK293-6E cells with yields exceeding 40 mg L -1 , which compares with the amounts obtained with wild-type RBD (319-541) in transient expression systems [1, 10, 24] and from stably transfected cell lines, [22] although yields of up to 90 mg L -1 from transient expressions have been achieved after transfection optimization. [9] While the native signal peptide of the SARS- 

Peptide mapping by mass spectrometry resulted in near complete coverage and confirmed the integrity of the N-and C-termini of the proteins ( Figure S1 , Supporting Information). Furthermore, the N-glycosylation patterns of all variants were comparable, with most detected compositions corresponding to complex-type N-glycans that are typically found on HEK293-derived glycoproteins ( Figures S2 and   S3 , Supporting Information). Wild-type RBD (319-541), tRBD, and the C538 mutants were found to be O-glycosylated (> 90%) at T323, whereas O-glycans were absent (< 1%) in the case of tRBD-TA (Figure 3) . Interestingly, the additional potential N-glycosylation site N536

in the mutant C538S was only scarcely utilized as less than 3% of the molecules contained N-glycans at this site (data not shown).

Testing of the thermal stability of the RBD mutants was performed with DSC. Interestingly, the midpoint transition temperature (T M ) of the SEC-purified dimeric wild-type RBD (49.6 • C) was considerably lower than that of monomeric RBD (53.0 • C), indicating partial misfolding ( Figure 4A ) and was similar as determined for a CHO-expressed cysteine-linked dimer (48.4 • C). [25] For most SEC-purified monomeric proteins, a single transition at about 53 • C was observed ( Figure 4A ).

Only the T M of tRBD-TA (52.3 • C) was slightly below that of wild-type RBD (319-541) and the other mutant variants.

In HIC, dimeric RBD eluted in multiple peaks at later time points than monomeric RBD ( Figure 4B ). This indicates the presence of a mixture of conformational states with a variable level of exposed hydrophobic residues, which probably results from misfolding and aggregation during the expression process. All SEC-purified monomeric RBD mutants eluted at the same time, indicating a similar degree of hydrophobicity. Consistent with the absence of the hydrophilic O-glycan attached to T323, elution of tRBD-TA was delayed by about 1 min ( Figure 4B ). Interestingly, the truncated variant tRBD displayed a broader elution peak. This could arise from microheterogeneity due to higher structural flexibility, which is possibly linked to inefficient formation of the salt bridge between the Cterminal residue K537 and E324 in this construct. Peak broadening was even more pronounced in the case of the RBD variant C538S, which contains an infrequently used additional N-glycosylation site at N536. It was encouraging to find that the stability of most SEC-purified monomeric RBD variants was not compromised by an incubation for 7 days in PBS at 25 • C as determined by SEC-HPLC and SDS-PAGE analysis ( Figure 4C ). This temperature was chosen as temperature-induced unfolding already starts at 37 • C ( Figure 4A Interestingly, the unpaired cysteine residue C538 of wild-type RBD (319-541) did not promote dimerization of the purified monomeric F I G U R E 3 O-glycan analysis of RBD variants by mass spectrometry. The N-terminal peptide contains a mixture of different O-glycans attached to T323, which consist of up to two hexose (H), N-acetylhexosamine (HexNAc, N) and N-acetylneuraminic acid (S) residues. Intens., ion intensity protein upon prolonged incubation. In both dimeric and monomeric wild-type RBD (319-541), C538 was < 10% reactive with thiol probes in its unreduced state ( Figure S4 , Supporting Information), which could result from oxidation or capping by endogenous compounds such as glutathione during protein synthesis and secretion.

Most SEC-purified monomeric RBD variants bound to immobilized ACE2-Fc, prepared as described recently, [26] with an affinity of 20- 

Except tRBD-TA (which was excluded from further studies due to its propensity to dimerize and the stability issues outlined above), all RBD variants were assayed for IgG immunoreactivity with a panel of convalescent COVID-19 sera (n = 124) and pre-pandemic human sera group medians were compared. Readouts with positive sera were 47to 58-fold higher than with control sera using monomeric RBD (319-541), tRBD and RBD mutants as diagnostic antigens. The ratio was even higher when using dimeric RBD (178-fold; p < 0.0001, Figure 5C ).

No significant differences between the groups were observed with the IgM-based serotest ( Figure 5D ). For a small subset of the COVID-19 sera (n = 28) we had data about the self-assessed course of disease available, which allowed us to color-code these data accordingly. For these sera, we observed that the magnitude of the IgG or IgM responses were very heterogeneous within the disease groups and did not reflect the severity of illness ( Figure 5C and D, right panels). Despite the described higher median ratio in MFI readouts between positive and negative sera with dimeric RBD, the overall diag- 

The SARS-CoV-2 RBD is a key antigenic component of protein-based vaccine candidates as well as diagnostic tests.[ 1 , 10 , 11 ] The tendency of RBD to form dimers has already been noticed at a very early stage of its structural and functional characterization. [9, [27] [28] [29] Nonetheless, the molecular features driving RBD dimerization have remained unclear so far. We and others have observed that C-terminally truncated RBD variants such as tRBD are less prone to dimerization and attributed this to the absence of the unpaired cysteine residue C538 in these constructs. [10, 22, 23, 30] However, removal of C538 by truncation could concomitantly increase the flexibility of K537 and thus interfere with the formation of a stabilizing salt bridge between K537 and E324. [12] We have therefore tested whether substitution of C538 with an uncharged amino acid of similar size (A, G, P, or S) would be a more suitable approach to reduce RBD dimerization while preserving its structural integrity. Our data indicate that tRBD and all four C538 mutants tested display comparable biophysical and seroreactive properties and do not show differences in ACE2-binding. Likewise, dimer formation was reduced to a similar extent. However, deletion or substitution of C538 is not sufficient to completely abolish RBD dimerization: the residual propensity of RBD variants lacking C538 to form dimers is particularly pronounced after the introduction of stability-enhancing mutations. [27] It is of note that all these mutations (I358F, Y365W, V367F, F392W) increase the hydrophobicity of the protein. This could promote its tendency to aggregate via interactions between hydrophobic residues that are transiently exposed during protein folding and quality control in the endoplasmic reticulum, [29] consistent with our observation that C538 is essentially unreactive once RBD has passed through the secretory pathway.

We have demonstrated that even small amounts of residual dimeric RBD (< 5%) can strongly affect kinetic studies of its interactions with ACE2 or other ligands. Interestingly, designed tandem repeat dimeric RBD resembles the monomer in ACE2 binding. [31] The stronger interaction of naturally formed dimer determined here can reflect differences in the spacing between the RBMs, or be a consequence of the bivalent nature of the ACE2-Fc ligand used in our study. Naturally formed dimeric RBD appears structurally impaired, judging from its lower thermostability as well as the considerable heterogeneity of the SEC-purified dimer preparations in HIC analysis. This may contribute to differences in the seroreactivity of monomeric and dimeric RBD forms. Indeed, it has been already demonstrated in pre-clinical mouse studies that RBD dimer preparations can be more immunogenic than the corresponding monomer. [31] Variable dimer content could mod- Under our culture conditions, up to 25% RBD in HEK293 supernatants was dimeric. Even higher dimer contents were observed after up-scaled production in HEK293-derived cell lines using stirred bioreactors and wave bags. [9] Dimer removal for the generation of homogeneous monomeric RBD preparations not only necessitates an additional purification step during vaccine manufacturing, up to 50% of the recombinant protein yield may need to be discarded. Therefore, RBD constructs that are less prone to dimerization are a preferred alternative for achieving high product yields. Recent studies reveal that also the choice of HEK Expi293F cells as expression host [9] as well as virusmediated DNA delivery instead of plasmid transfection results in less dimer. [32] Separation of monomeric and dimeric RBD is usually accomplished by preparative SEC, which poses a challenge for upscaling of the purification procedure. [11, 28] We have found that monomeric and dimeric RBD can be also effectively separated by HIC, which is superior to SEC with respect to its scalability and thus easier to implement in industrial production, and the feasibility of HIC-based RBDpurification steps in its large-scale downstream processing has been already demonstrated. [33] Elimination of C538 by C-terminal truncation or a point mutation did not result in major changes in the immunoreactivity of RBD with sera from SARS-CoV-2-infected individuals when utilized as diagnostic antigen in Luminex bead-based tests as well as ELISA assays.

We used COVID-19 serum samples from non-hospitalized individuals with disease symptoms ranging from asymptomatic to severe, which is reflected by the heterogeneity in the observed seroreactivities. Sera was drawn maximum 4 months after acute SARS-CoV-2

infection. Within such a short time frame, an earlier onset of antibody waning makes IgM responses usually much more dynamic than IgG responses. [34] Interestingly, control sera displayed a unique seroreactivity pattern with dimeric RBD, suggesting an antigen-specific effect.

Our HIC data suggests that the RBD dimer is a conformationally heterogeneous species with a certain degree of misfolding. This may have caused higher unspecific binding with control sera and the detection antibody, which after blank correction ultimately yielded a broader spectrum of fluorescence readouts than with other antigens. While our data suggest that the usually unspecified dimer content of commercial RBD preparations will not affect the overall performance of seroassays, dimer presence could affect the long-term stability of RBD and thus diagnostic performance after extended storage.

It is well established that proper N-glycosylation of N331 and N343

is important for correct folding of the RBD. [30, 31, 35] Although it has been reported before that RBD also contains O-glycans, [18, 36, 37] the functional relevance of RBD O-glycosylation has been hitherto not addressed In our RBD preparations derived from HEK293-6E cells, T323 is consistently O-glycosylated in an almost quantitative manner (> 90%). Other reports have also noted substantial O-glycosylation of T323 in other monomeric S-protein variants. [36, 37] Interestingly, Oglycosylation of T323 is far less pronounced in the context of fulllength S-protein trimers, [37] [38] [39] [40] indicating that this site is shielded upon trimer formation and thus not accessible to glycosylation enzymes once oligomerization has taken place. In RBD, T323 O-glycosylation, characterized as disialyl Core 1 and Core 2 structures [39] could be required to prevent oligomerization of RBD monomers by masking an otherwise aggregation-prone hydrophobic peptide stretch or by balancing the overall charge of the protein. The mutation of T323 into alanine essentially eliminated O-glycosylation of the N-terminal RBD peptide and concomitantly increased the propensity of the protein to form dimers as well as lowered its thermal stability. Other studies of RBD mutants with N-terminal truncations that removed T323 also report monomer loss upon incubation at room temperature. [24] However, the capacity of RBD to interact with ACE2 was thereby not compromised, which is consistent with structural data demonstrating that T323 is not located in the proximity of the ACE2-binding site. [12] In conclusion, our study has revealed that the dimerization propensity of the most widely used SARS-CoV-2 S-protein RBD variant encompassing amino acids 319-541 can be reduced by truncation or substitution of the unpaired cysteine residue C538 without compromising the biophysical properties and seroreactivity of the protein.

Furthermore, we have shown that the O-glycans attached to T323 also counteract RBD dimerization. These findings will support ongoing efforts to design improved RBD-based vaccines and diagnostic reagents. 

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The data that support the findings of this study are available within this article and supporting information, and on request from the corresponding author.

Klausberger https://orcid.org/0000-0001-8409-454X

Nikolaus F. Kienzl https://orcid.org/0000-0001-8057-3930

Elisabeth Laurent https://orcid.org/0000-0002-5234-5524

Lukas Mach https://orcid.org/0000-0001-9013-5408

Gordana Wozniak-Knopp https://orcid.org/0000-0002-4069-070X

A serological assay to detect SARS-CoV-2 seroconversion in humans

SARSa CoVa 2 seroconversion in humans: A detailed protocol for a serological assay, antigen production, and test setup

Virus-like particles as an instrument of vaccine production

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Structure, dynamics, receptor binding, and antibody binding of the fully glycosylated full-length SARS-CoV-2 spike protein in a viral membrane

Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Production of higha quality SARSa CoVa 2 antigens: Impact of bioprocess and storage on glycosylation, biophysical attributes, and ELISA serologic tests performance

Grabherr, R. (2021). A comprehensive antigen production and characterisation study for easy-to-implement

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Expression of SARS-CoV-2 surface glycoprotein fragment 319a 640 in E. coli, and its refolding and purification

Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cells

Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana

Potently neutralizing and protective human antibodies against SARS-CoV-2

Beyond shielding: The roles of glycans in the SARS-CoV-2 spike protein

Site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells

The FoldX web server: An online force field

A graphical interface for the FoldX forcefield

A new coronavirus associated with human respiratory disease in China

High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the EEF1A1-based plasmid vector

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Comparative immunomodulatory evaluation of the receptor binding domain of the SARS-CoV-2 spike protein; a potential vaccine candidate which imparts potent humoral and Th1 type immune response in a mouse model

RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates

Generation of enzymatically competent SARSa CoVa 2 decoy receptor ACE2a Fc in glycoengineered Nicotiana benthamiana

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate

N-Glycosylation of the SARS-CoV-2 Receptor Binding Domain Is Important for Functional Expression in Plants

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

A universal design of Betacoronavirus vaccines against COVID-19

Rapid high-yield production of functional Sars-Cov-2 receptor binding domain by viral and non-viral transient expression for preclinical evaluation

Process development and scale-up optimization of the SARS-CoV-2 receptor binding domaina based vaccine candidate

The dynamic changes of serum IgM and IgG against SARSa CoVa 2 in patients with COVIDa 19

Deducing the N-and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2

N-and O-Glycosylation of the SARS-CoV-2 spike protein

Site-specific glycan analysis of the SARS-CoV-2 spike

Suppression of O-linked glycosylation of the SARS-CoV-2 spike by quaternary structural restraints

Site-specific characterization of SARS-CoV-2 spike glycoprotein receptor-binding domain

Virusreceptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor

Designed SARS-CoV-2 receptor binding domain variants form stable monomers